Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Drops -122.97% From Highs, Now What? – Marketing Sentinel
Home  »  Business   »  Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Drops ...

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Drops -122.97% From Highs, Now What?

During the last session, Iovance Biotherapeutics Inc. (NASDAQ:IOVA)’s traded shares were 2.69 million, with the beta value of the company hitting 0.48. At the end of the trading day, the stock’s price was $12.54, reflecting an intraday gain of 4.15% or $0.5. The 52-week high for the IOVA share is $27.96, that puts it down -122.97 from that peak though still a striking 50.72% gain since the share price plummeted to a 52-week low of $6.18. The company’s market capitalization is $2.06B, and the average intraday trading volume over the past 10 days was 2.32 million shares, and the average trade volume was 5.10 million shares over the past three months.

Iovance Biotherapeutics Inc. (IOVA) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.90. IOVA has a Sell rating from 0 analyst(s) out of 14 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 2 suggest Overweight, and 10 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.61.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) trade information

Iovance Biotherapeutics Inc. (IOVA) registered a 4.15% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.15% in intraday trading to $12.54 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is 7.64%, and it has moved by 4.59% in 30 days. Based on these gigs, the overall price performance for the year is -45.00%. The short interest in Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is 19.94 million shares and it means that shorts have 3.79 day(s) to cover.

The consensus price target of analysts on Wall Street is $27.23, which implies an increase of 53.95% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $13.00 and $43.00 respectively. As a result, IOVA is trading at a discount of -242.9% off the target high and -3.67% off the low.

Iovance Biotherapeutics Inc. (IOVA) estimates and forecasts

Statistics show that Iovance Biotherapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Iovance Biotherapeutics Inc. (IOVA) shares have gone down -24.37% during the last six months, with a year-to-date growth rate less than the industry average at -11.66% against 1.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -15.10% this quarter and then drop -12.70% in the quarter after that.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -3.80%. While earnings are projected to return -18.90% in 2022.

IOVA Dividends

Iovance Biotherapeutics Inc. is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA)’s Major holders

Iovance Biotherapeutics Inc. insiders own 0.47% of total outstanding shares while institutional holders control 104.70%, with the float percentage being 105.19%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 354 institutions own stock in it. As of Mar 30, 2022, the company held over 12.34 million shares (or 7.85% of all shares), a total value of $205.49 million in shares.

The next largest institutional holding, with 12.2 million shares, is of Perceptive Advisors Llc’s that is approximately 7.76% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $203.15 million.

Also, the Mutual Funds coming in first place with the largest holdings of Iovance Biotherapeutics Inc. (IOVA) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Hartford Mid Cap Fund. Data provided on Jun 29, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 8.63 million shares. This amounts to just over 5.49 percent of the company’s overall shares, with a $95.25 million market value. The same data shows that the other fund manager holds slightly less at 5.81 million, or about 3.70% of the stock, which is worth about $88.06 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]